Urine and blood clues may predict kidney cancer treatment success
NCT ID NCT07406646
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study involved 91 adults with advanced kidney cancer. Researchers collected blood and urine samples over 16 weeks to see if changes in tiny particles called exosomal miRNAs could predict whether treatment was working. The goal was to find a simple, non-invasive way to monitor treatment response without relying only on scans.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED KIDNEY CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Oncology Ljubljana
Ljubljana, 1000, Slovenia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict who needs extra therapy after kidney cancer surgery?
- Can a Two-Drug combo outsmart advanced cancers?
- Can a rapid drug switch outsmart advanced kidney cancer?
- Can a new nucleotide analogue boost cancer treatment?
- Can a blast of radiation make immunotherapy work better against kidney cancer?
- Can reprogrammed immune cells take on hard-to-treat kidney cancer?